Today, we have signed a joint research agreement on cancer immunotherapy between the National Cancer Center Japan and our company. By combining the know-how related to cancer immunotherapy possessed by the National Cancer Research Center Japan and the knowledge that we have accumulated in clinical practice of cancer immunotherapy, we will conduct research and development for the more effective cancer immunotherapy.

Outline of joint research

Joint research theme: Development of bispecific antibody (BsAb) therapy and Hexa-Complex Immunotherapy

Joint research period: From July 1st, 2020 to June 30th, 2023